USP comments to FDA on Docket No. FDA-2021-D-1047 for “Q13 Continuous Manufacturing of Drug Substances and Drug Products”. Comments were submitted in 2021.
Public Policy
USP comments to FDA on Docket No. FDA-2021-D-1047 for “Q13 Continuous Manufacturing of Drug Substances and Drug Products”. Comments were submitted in 2021.